

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |  |  |   |
|--|--|--|---|
| (51) International Patent Classification <sup>6</sup> :<br><b>C12N 15/53, 9/02, G01N 33/50, C12Q 1/68, C12N 1/19, 1/21, 5/10</b>   |  | <b>A1</b>  | (11) International Publication Number: <b>WO 95/25798</b>         |
|  |  |  | (43) International Publication Date: 28 September 1995 (28.09.95) |
| (21) International Application Number: <b>PCT/GB95/00629</b>   |  | (74) Agent: LOCKWOOD, Peter, Brian; Ministry of Defence (FE), Directorate of Intellectual Property Rights, Empress State Building, Room 2002, Lillie Road, London SW6 1TR (GB).  |   |
| (22) International Filing Date: 22 March 1995 (22.03.95)   |  |  |   |
| (30) Priority Data:<br>9405750.2 23 March 1994 (23.03.94) GB<br>9501170.6 20 January 1995 (20.01.95) GB  |  | (81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). |   |
| (71) Applicant (for all designated States except US): THE SECRETARY OF STATE OF DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND [GB/GB]; Whitehall, London SW1A 2HB (GB).  |  | Published<br><i>With international search report.</i><br><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>   |   |
| (72) Inventors; and<br>(75) Inventors/Applicants (for US only): LOWE, Christopher, Robin [GB/GB]; University of Cambridge, Tennis Court Road, Cambridge, Cambridgeshire CB2 1QT (GB). WHITE, Peter, John [GB/GB]; University of Cambridge, Tennis Court Road, Cambridge, Cambridgeshire CB2 1QT (GB). MURRAY, James, Augustus, Henry [GB/GB]; University of Cambridge, Tennis Court Road, Cambridge, Cambridgeshire CB2 1QT (GB). SQUIRREL, David, James [GB/GB]; CBDE, Porton Down, Salisbury, Wiltshire SP4 0JQ (GB).  |  |  |   |
| (54) Title: LUCIFERASES  |  |  |   |
| (57) Abstract<br><p>Proteins are provided having luciferase activity with greater heat stability than wildtype luciferases by replacing the glutamate equivalent to that at position 354 of <i>Photinus pyralis</i> luciferase or 356 of <i>Luciola</i> luciferases with an alternative amino acid, particularly lysine. DNA, vectors and cells that encode for and express the proteins are also provided as are test kits and reagents for carrying out luminescence assays using the proteins of the invention. Preferred proteins have a second replaced amino acid at a position equivalent to position 215 of <i>Photinus pyralis</i> luciferase or 217 of <i>Luciola</i> luciferases.</p> |  |  |   |

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |                                       |    |                          |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria                  | GB | United Kingdom                        | MR | Mauritania               |
| AU | Australia                | GE | Georgia                               | MW | Malawi                   |
| BB | Barbados                 | GN | Guinea                                | NE | Niger                    |
| BE | Belgium                  | GR | Greece                                | NL | Netherlands              |
| BF | Burkina Faso             | HU | Hungary                               | NO | Norway                   |
| BG | Bulgaria                 | IE | Ireland                               | NZ | New Zealand              |
| BJ | Benin                    | IT | Italy                                 | PL | Poland                   |
| BR | Brazil                   | JP | Japan                                 | PT | Portugal                 |
| BY | Belarus                  | KE | Kenya                                 | RO | Romania                  |
| CA | Canada                   | KG | Kyrgyzstan                            | RU | Russian Federation       |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan                    |
| CG | Congo                    | KR | Republic of Korea                     | SE | Sweden                   |
| CH | Switzerland              | KZ | Kazakhstan                            | SI | Slovenia                 |
| CI | Côte d'Ivoire            | LI | Liechtenstein                         | SK | Slovakia                 |
| CN | China                    | LK | Sri Lanka                             | SN | Senegal                  |
| CS | Czechoslovakia           | LU | Luxembourg                            | TD | Chad                     |
| CZ | Czech Republic           | LV | Latvia                                | TG | Togo                     |
| DE | Germany                  | MC | Monaco                                | TJ | Tajikistan               |
| DK | Denmark                  | MD | Republic of Moldova                   | TT | Trinidad and Tobago      |
| ES | Spain                    | MG | Madagascar                            | UA | Ukraine                  |
| FI | Finland                  | ML | Mali                                  | US | United States of America |
| FR | France                   | MN | Mongolia                              | UZ | Uzbekistan               |
| GA | Gabon                    |    |                                       | VN | Viet Nam                 |

LUCIFERASES.

The present invention relates to novel proteins having luciferase activity and to DNA and vectors encoding for their expression. Particularly the present invention provides luciferases having heat stability at temperatures above 30°C.

Firefly luciferase catalyses the oxidation of luciferin in the presence of ATP,  $Mg^{2+}$  and molecular oxygen with the resultant production of light. This reaction has a quantum yield of about 0.88 (see DeLuca & McElroy (1978) and Seliger & McElroy (1960)) and this light emitting property has led to its use in luminometric assays where ATP levels are being measured.

Luciferase is obtainable directly from the bodies of insects such as fireflies or glow-worms or by expression from microorganisms including recombinant DNA constructs encoding for the enzyme. Four significant species of firefly from which the enzyme may be obtained, or DNA encoding for it may be derived, are the Japanese GENJI and HEIKE fireflies Luciola cruciata and Luciola lateralis, the East European Firefly Luciola mingrelica and the North American firefly (Photinus pyralis). The glow-worm Lampyris noctiluca is a further source with the amino acid sequence of its luciferase having 84% homology to that of Photinus pyralis.

The heat stability of wild and recombinant type luciferases is such that they lose activity quite rapidly when exposed to temperatures in excess of about 30°C, particularly over 35°C. Such instability renders the enzyme deficient when used or stored at high ambient temperatures or if heat induced increase in reaction rate is required. It is known that Japanese firefly luciferase can be stabilised against heat inactivation by mutating it at its position 217 to replace a threonine residue by an isoleucine residue (Kajiyama & Nakano (1993) Biochemistry 32 page 13795 to 13799). In this manner the thermal and

pH stability and the specific activity of the enzyme were increased. The heat stabilisation of Photinus pyralis and Luciola mingrelica luciferases has not yet been reported.

The present inventors have now provided novel luciferases having increased heat stability over wild type luciferases by replacing a glutamate residue present in a sequence conserved in each of Photinus pyralis, Luciola mingrelica, Luciola lateralis and Luciola cruciata with alternative amino acids, particularly lysine or arginine. This glutamate is found at position 354 in Photinus pyralis luciferase, at the third amino acid of the conserved amino acid sequence TPEGDDKPGA found in the luciferases of this and the other species.

Thus in the first aspect of the invention there is provided a protein having luciferase activity and having over 60% homology of amino acid sequence with that of Photinus pyralis, Luciola mingrelica, Luciola cruciata or Luciola lateralis characterised in that the amino acid residue corresponding to residue 354 of Photinus pyralis luciferase and residue 356 of Luciola mingrelica, Luciola cruciata and Luciola lateralis luciferase is an amino acid other than glutamate.

The amino acid may be a naturally occurring amino acid or may be a so called unusual amino acid such as an modified naturally occurring amino acid or an analogue of such. Analogues of amino acids other than glutamate will be understood to be those compounds that have equivalent effect on the protein to the amino acid of which they are analogues. Typical unusual amino acids are those as set out in the US and European Patentin Manuals and the Rules of Practice in Patent Cases: application disclosures containing nucleotide and/or amino acid sequences: modified and unusual amino acids.

Preferably the protein is characterised in that it comprises an amino acid sequence XGDDKPGA wherein X is the amino acid other than glutamate. More preferably the protein comprises the amino acid

sequence TPXGDDKPGA and preferably, for thermostability, X is any amino acid other than aspartic acid, proline or glycine; still more preferably it is tryptophan, valine, leucine, isoleucine or asparagine but most preferably is lysine or arginine, or analogue of any of these.

It will be realised that some species may have luciferases with one or two amino acids different in this conserved TPXGDDKPA region, but all active proteins corresponding to such luciferases that are altered to the extent that the amino acid at position three in the sequence is not glutamate are provided for by the present invention.

In preferred forms of the present invention the protein of the invention also has the amino acid at the position corresponding to amino acid 217 of the Luciola firefly luciferases or 215 of Photinus pyralis changed to a hydrophobic amino acid, preferably to isoleucine, leucine or valine, as described in EP 0524448 A. Such change has been found to result in an increase in thermostability over the 354 change alone; thus the two changes have effects that are substantially independent of each other and which may be used together.

In a second aspect of the invention there is provided DNA encoding for the protein of the invention and in a third aspect there is provided a vector, particularly a plasmid, comprising a *luc* gene (the gene encoding for luciferase) in such a form as to be capable of expressing the protein of the invention. Such forms are those where the vector includes DNA sequences capable of controlling the expression of the protein of the invention such that when incorporated into a microorganism host cell the protein may readily be expressed as required, if necessary by addition of suitable inducers.

The *luc* genes for Photinus pyralis, Luciola mingrelica, Luciola cruciata and Luciola lateralis are all known and isolatable by standard molecular biology techniques. Photinus pyralis *luc* gene is commercially available from Promega as the plasmid pGEM. Thus

convenient methods and sources for deriving starting material for production of DNA of the invention are (i) use of naturally occurring firefly genomic DNA and amplifying the *luc* gene from it using eg, PCR, (ii) pGEM and (iii) pGLf37 plasmid of Kajiyama & Nakano. Further genes encoding for proteins having luciferase activity, ie. the activity of oxidising luciferin with the emission of light, will also be suitable sources for starting material for obtaining a DNA, and ultimately through gene expression, a protein of the invention.

Suitable vectors for use in manipulating wild type or other *luc* gene DNA in order to produce the DNA of the invention will be any vector in which the DNA can be contained within while alteration of the naturally occurring glutamate to an alternative amino acid is carried out. For chemically induced mutagenesis, eg. using agents such as hydroxylamine, this is not particularly critical and many suitable vectors will occur to those skilled in the art that will allow easy manipulation of the gene before and after the mutagenic process.

It may be preferred to specifically mutate the *luc* gene at the glutamate and thus a site directed mutagenesis operation will be required. Such operations may be most easily carried out in vectors and these will be well known to those skilled in the art.

For expression of *luc* genes of wild and known type, and those of the present invention suitable vectors include pKK223-3, pDR540 (available from Boehringer Mannheim) and pT7-7; the first two having the *tac* promoter under control of the lactose repressor allowing expression to be induced by presence of isopropyl-thiogalactoside (IPTG). pT7-7 allows control by the T7-RNA polymerase promoter and thus provides the basis for a very high level of gene expression in *E. coli* cells containing T7 RNA polymerase. Of these vectors expression is found to be highest when the *luc* genes are inserted into the pT7-7 vector.

Expression of luciferase from a *luc* gene inserted into pKK223-3 and

pDR540 results in the expression of wild-type N-terminal sequence luciferase whilst expression from a *luc* gene inserted into pT7-7 results in synthesis of a fusion protein with extra N-terminal amino acids M-A-R-I-Q. The ribosome binding site and start codon of the *luc* gene in each of the vectors with the *luc* gene present (named constructs pPW204, pPW116 and pPW304) are shown in Table 1 of the Examples.

A third aspect of the present invention provides cells capable of expressing the proteins of the invention; methods for producing such proteins using these cells and test kits and reagents comprising the proteins of the invention. Also provided are assay methods wherein ATP is measured using luciferin/luciferase reagents, as is well known in the art, characterised in that the luciferase is a protein of the invention. Luciferase preparations of the invention are relatively thermostable at 30-70°C, particularly 37-60°C, and especially 40-50°C as compared to the wild-type and recombinant wild-type luciferases.

Any cell capable of expressing heterologous protein using DNA sequences in its DNA, or in vectors such as plasmids contained in the cell, may be used to express the proteins of the invention. Typical of such cells will be yeast and bacterial cells such as Saccharomyces cerevisiae and Escherichia coli cells, but many other host organisms suitable for the purpose of protein expression will occur to those skilled in the art. Insect cells may be preferred as the protein is an insect protein. The protein may be expressed as a protein of similar structure to native and known recombinant luciferases, or may be expressed as a fusion or conjugate of such proteins with other amino acids, peptides, proteins or other chemical entities, eg. the M-A-R-I-Q sequence above.

It will be realised by those skilled in the art that certain hosts may have particular codon preferences, eg. bacteria in some cases use different codons to yeast, and thus the DNA incorporated into such a host may advantageously be altered to provide a degenerate codon for a given amino acid that will give more favourable expression in that

host. Such degenerate DNAs are of course included in the scope of the DNA of the invention.

E. coli BL21(DE3) is one suitable host and has the T7 RNA polymerase integrated stably into its chromosome under control of the inducible lacUV5 promoter and is thus compatible with pT7-7 derived constructs. E. coli B strains like BL21 lack the *lon* protease and the *ompT* outer membrane protease. These deficiencies can help to stabilise the expression and accumulation of foreign proteins in E. coli. Assays of crude extracts of E. coli BL21(DE3) containing each of the three expression constructs described above indicated that the highest levels of expression of luciferase were obtained from cells containing the construct pPW304 (see Table 2).

The mutant proteins of the invention provide advantages other than thermostability. It has been found that the mutation of the amino acid at position Photinus 354/Luciola 356 provided a change in wavelength of light emitted on oxidation of luciferin dependent upon the amino acid or analogue with which the glutamate is substituted. Thus the invention also provides luciferases for use as specific binding agent labels or reporter genes which report back identity as a specific wavelength of light when the luciferin oxidation using their protein products; such property gives utility to such mutations as glycine, proline and aspartate. A further advantage of the proteins of the invention, deriving from their increased thermostability, is the ability to produce them at higher temperature, eg. at 37°C or above, with correspondingly increased yield, as is exemplified below.

The proteins, DNA, vectors and cells of the invention will now be described by way of illustration only by reference to the following non-limiting Examples, Figures, Tables and Sequence listing. Further proteins, conjugates of proteins, DNA, vectors and cells, and assays and test kits incorporating any of the above will occur to those skilled in the art in the light of these.



## FIGURES

Figure 1: shows a restriction map of plasmid pPW204 derived from pKK223-3 by insertion of a *luc* gene as described in the Examples below.

Figure 2: shows a restriction map of plasmid pPW116 derived from pDR540 by insertion of a *luc* gene as described in the Examples below.

Figure 3: shows a restriction map of plasmid pPW304 derived from pT7-7 by insertion of a *luc* gene as described in the Examples below.

Figure 4: shows a restriction map of plasmid pPW601a derived from pDR540 and BamH1/Sst1 fragment from pGEM-*luc* with the Xho site removed.

Figure 5: shows a graph of heat inactivation of recombinant and wild type *Photinus* luciferases (Sigma) incubated at a given temperature for 20 minute periods as described in the Examples below.

Figure 6: shows a graph of luciferase activity in crude extracts of *E. coli* BL21(DE3)pPW304 during growth at different temperatures.

Figure 7: shows a graph of heat inactivation of activity of luciferases derived from pPW304 and pPW304M-1 (plasmid of the invention encoding such that lysine replaces glutamate 354).

Figure 8: shows a graph of time dependent inactivation of Sigma wild type, and pPW304 and pPW304M-1 recombinant luciferases at 37°C.

Figure 9: shows a restriction map of pT7-7 after Tabor.

Figure 10: shows a graph illustrating heat inactivation in Promega lysis buffer at 40°C of activity of crude cell extracts of luciferase expressing *E. coli* of the invention expressing luciferases having

substitutions of alanine, valine, leucine, isoleucine, tyrosine, phenylalanine, tryptophan, glutamine, histidine, asparagine, methionine, arginine, lysine, serine, threonine and cysteine respectively for the wild type glutamate at position 354.

Figure 11: shows a graph illustrating heat inactivation of activity of purified double mutant luciferase having the E354K Lysine and the A215L Leucine changes at 47°C in phosphate buffer as compared to the single mutants A215L and E354K.

Figure 12: shows a graph of % initial activity of the Lysine E354K mutant, recombinant wild-type and native firefly luciferases remaining against time at 37°C in pH7.75 HEPES buffer with 0.02% azide.

Figure 13: shows a graph of luciferase expression at 37°C for recombinant wild-type, E354K single and E354K+A215L double mutants with increase in optical density as a measure of culture cell density plotted against luciferase activity.

Figure 14: shows a graph of % initial activity against time of 10ng/ml of each of the A215L and E354K single, A215L+E354K double, recombinant and Sigma wild-type luciferases over 5 hours in HEPES, pH7.75 containing 1%BSA and 0.02% azide at 37°C.

Figure 15: shows a graph of % initial activity against time of 10ng/ml of each of the A215L and E354K single, A215L+E354K double, recombinant and Sigma wild-type luciferase over 5 hours in HEPES pH7.75 containing 1%BSA, 0.02% azide, 2mM EDTA and 2mM DTT at 37°C.

#### SEQUENCE LISTING:

The sequence listing provided at the end of this specification describes DNA and amino acid sequences as follows:

SEQ ID NO 1: shows the DNA sequence of a DNA encoding for luciferase

of the invention wherein the Photinus pyralis wild-type codon at 1063 to 1065 is mutated; for lysine the base at 1063 is mutated to an A.

SEQ ID No 2: shows the amino acid sequence of a protein of the invention wherein the Photinus pyralis wild-type amino acid 354 glutamate has been changed to another amino acid.

SEQ ID No 3: shows the sequence of the oligonucleotide used for the SDM mutation of pPW601 to give a lysine instead of glutamate at position 354 in Example 2.

SEQ ID No 4: shows the sequence of the oligonucleotide used for the SDM mutation of pPW601 to give leucine at position 215 in Example 5.

SEQ ID No 5: shows the amino acid sequence of a protein of the invention wherein the Photinus pyralis wild-type amino acid 354 glutamate has been changed to any other amino acid and the 215 amino acid changed to a leucine.

#### EXAMPLES

EXAMPLE 1: Production of plasmids containing DNA of the invention.  
Plasmids pKK223-3 and pDR540 were obtained from Boehringer Mannheim; pDR540 is also available from Pharmacia.

Plasmid pT7-7 (see Current protocols in Molecular Biology Vol II Section 16.2.1) was obtained from Stan Tabor, Dept of Biol Chem, Harvard Medical School, Boston, Mass 02115 and (as shown in Figure 8) contains T7 RNA polymerase promoter  $\phi$ 10 and the translation start site for the T7 gene 10 protein (T7 bp 22857 to 22972) inserted between the PvuII and ClaI sites of pT7-5. Unique restriction sites for creation of fusion proteins (after filling in 5' ends) are Frame 0: EcoRI; Frame 1: NdcI, SmaI, ClaI; Frame 2: BamHI, SalI, HindIII. SacI site of the original polylinker is removed by deletion and an additional XbaI site is provided upstream of the start codon.

Firefly luciferase (prepared from a crystalline suspension, Cat No L9009), coenzyme A and ATP were obtained from Sigma Chemical Co. Beetle luciferin potassium salt was obtained from Promega. Cell extracts were prepared as described in the Promega technical bulletin No 101. Aliquots of *E. coli* cultures were lysed in cell culture lysis reagent (25mM Tris-phosphate, pH7.8, 2mM DTT, 2mM EDTA, 10% glycerol, 1% Triton X-100, 2.5mg/ml BSA, 1.25mg/ml lysozyme) for 10 minutes at room temperature and then stored on ice prior to assay.

Luciferase activity of cell lines was assayed by monitoring bioluminescence emitted by colonies by transferring these to nylon filters (Hybond N, Amersham) and then soaking the filters with 0.5mM luciferin in 100mM sodium citrate buffer pH5.0 (Wood & DeLuca, (1987) Anal Biochem 161 p501-507). Luciferase assays in vitro were performed at 25°C using 125µl of assay buffer (20mM Tricine, 1mM MgSO<sub>4</sub>, 0.1mM EDTA, 33.3mM DTT, 0.27mM coenzyme A, 0.47mM luciferin, 0.53mM ATP and 1 to 2µl of sample). The final pH of the assay cocktail was 7.8 and light measurements were made with a BioOrbit 1250 luminometer.

For production of non-specific chemical mutations of DNA, plasmids containing *luc* genes were treated according to the method of Kironde et al (1989) Biochem. J. 259, p421-426 using 0.8M hydroxylamine, 1mM EDTA in 0.1mM sodium phosphate pH6.0 for 2 hours at 65°C. The mutagenised plasmid was desalted on a G60 DNA grade Nick column (Pharmacia) followed by transformation into *E. coli* BL21(DE3).

Heat inactivation studies were carried out by incubating crude cell extracts having luciferase activity at various temperatures for 20 minutes and measuring remaining activities. In studies with the purified luciferase obtained from Sigma the enzyme was diluted in Promega lysis buffer prior to inactivation. For time dependent studies Eppendorf tubes containing 50µl of crude cell extract or Sigma luciferase in lysis buffer were incubated at 37°C. At various times a

tube was removed and cooled on ice prior to assay. The remaining activity was expressed as per cent of original activity.

Relative levels of expression of luciferase from each of the constructs pPW204, pPW116 and pPW304 are 0.1:0.5:1.0 from *E. coli* BL21(DE3). Cells were grown in LB at 37°C to an OD 600 of 0.3 then induced with IPTG and growth allowed to continue for 4 hours after which crude extract was prepared and luciferase activity measured.

TABLE 1: Ribosome binding sites (underlined) and start codons in the expression constructs used in Example 1.

pPW304    AAGGAGATATACAT ATG\* CGT AGA ATT CAA ATG  
pPW116   AGGAAACAGGATCCA ATG\*  
pPW204    AGGAAACAGCAA ATG\*

The site directed mutagenesis required to convert the glutamate to an alternative amino acid was carried out using the following protocol. Because the glutamate to lysine mutation lies within a unique *Ava*I restriction site, and thus destroys it, it is possible to use a single oligonucleotide as the mutagenic and selection oligonucleotide.

Site Directed Mutagenesis Protocol:

Plasmid selected is denatured and annealed with a selection/mutagenic oligonucleotide for lysine: 5'-CATCCCCCTTGGGTGTAATCAG-3' with the underlined T being the mismatch. The mutant DNA strand is synthesised and ligated and the whole primary restriction digested with *Ava*I.

Transformation into cells, here *E. coli* BMH 71-18 mut S cells, was carried out using a Bio-Rad Gene Pulser version 2-89. Harvested cells and purified mixed plasmid pool containing mutated and parental plasmids were provided and secondary restriction digest with *Ava*I was carried out before transformation into *E. coli* JM109 cells. These cells were plated on selective media (LB agar + 50 µg/ml ampicillin) and clones screened by purifying their plasmid DNA and analysing for

the loss of the *Ava*I restriction site. Plasmid DNA was purified in each case using the alkaline lysis method of Birnboim and Doly (1979) *Nucleic Acids Research* 7, p1513. Precise protocols were as described in the Transformer<sup>RTM</sup> Site -Directed Mutagenesis Kit (Version 2) sold by Clontech Laboratories Inc (US) catalog No K1600-1.

The restriction map for pPW601a, a variant of pPW116 derived from Pharmacia pDR540 and *Bam*HI/*Sst*I fragment from pGEM-*luc* with the *Xho* site destroyed is shown as Figure 4. Site directed mutagenesis was carried out as described above and in the Clontech instructions such as to convert the wild-type *Photinus luc* gene inserted therein into a sequence as shown in SEQ ID No 1 wherein 1063-1065 is AAG, with expressed protein of amino acid sequence modified at position 354 as shown in SEQ ID No 2 to Lysine.

#### EXAMPLE 2: Heat stability of luciferases:

The heat stability of various luciferases expressed by unmodified and modified (ie. of the invention) *luc* genes in vectors in *E. coli* produced as described above was determined and results are shown in Figures 5 to 8.

A comparison of  $t^{1/2}$  (half-life) of the activity of 50 $\mu$ g/ml luciferase at 43.5°C in 50mM potassium phosphate buffer pH7.8, 1mM EDTA, 0.2%(w/v) BSA, 1mM DTT and 10% ammonium sulphate shows 50% activity remaining to be reached at times as follows:

|                            |  |
|----------------------------|--|
| Sigma wildtype luciferase: | $t^{1/2}$ reached in approximately 1.5 minutes |
| pPW601 (354=glutamate):    | $t^{1/2}$ reached ' ' ' ' 5 ' '                |
| pPW601aK (354=lysine):     | $t^{1/2}$ reached ' ' ' ' 30 ' '               |

Thus clearly from the aforesaid figures it can be seen that replacing the 354 glutamate with lysine increases heat stability of luciferase at least up to 43.5°C.

EXAMPLE 3: Heat stability of luciferase:

The heat stability of a number of luciferases expressed by SDM modified *luc* genes corresponding to other position 354 mutations of the invention in vectors in *E. coli* produced by methods analogous to that as described in Example 1 was determined and results are graphically shown in Figure 10.

A comparison of  $t^{1/2}$  at 40°C in Promega lysis buffer was carried out and results obtained in  $t^{1/2}$  in minutes as:

|                              |   |
|------------------------------|---|
| pPW601aK (354=lysine)        | $t^{1/2}$ reached in approximately 13 minutes |
| pPW601aR ('' =arginine)      | $t^{1/2}$ reached '' '' '' 13 ''              |
| pPW601aL ('' =leucine)       | $t^{1/2}$ reached '' '' '' 10 ''              |
| pPW601aI ('' =isoleucine)    | $t^{1/2}$ reached '' '' '' 10 ''              |
| pPW601aN ('' =asparagine)    | $t^{1/2}$ reached '' '' '' 10 ''              |
| pPW601aV ('' =valine)        | $t^{1/2}$ reached '' '' '' 9 minutes          |
| pPW601aW ('' =tryptophan)    | $t^{1/2}$ reached '' '' '' 8 ''               |
| pPW601aA (354=alanine)       | $t^{1/2}$ reached '' '' '' 6.5''              |
| pPW601aY ('' =tyrosine)      | $t^{1/2}$ reached '' '' '' 6.5''              |
| pPW601aM ('' =methionine)    | $t^{1/2}$ reached '' '' '' 5.5''              |
| pPW601aF ('' =phenylalanine) | $t^{1/2}$ reached '' '' '' 5 ''               |
| pPW601aH ('' =histidine)     | $t^{1/2}$ reached '' '' '' 5 ''               |
| pPW601aT ('' =threonine)     | $t^{1/2}$ reached '' '' '' 4.5''              |
| pPW601aQ ('' =glutamine)     | $t^{1/2}$ reached '' '' '' 4.5''              |
| pPW601aC ('' =cysteine)      | $t^{1/2}$ reached '' '' '' 4 ''               |
| pPW601aS ('' =serine)        | $t^{1/2}$ reached '' '' '' 3.5''              |
| pPW601aE ('' =glutamic acid) | $t^{1/2}$ reached '' '' '' 1 ''               |
| pPW601aD ('' =aspartic acid) | $t^{1/2}$ reached '' '' '' 1 ''               |
| pPW601aP ('' =proline)       | $t^{1/2}$ reached '' '' '' 1 ''               |
| pPW601aG ('' =glycine)       | $t^{1/2}$ reached '' '' '' <1 ''              |

EXAMPLE 4: Stability of Luciferases at 37°C and room temperature.

Luciferases of pPW601K lysine mutation (86ng/ml), recombinant wild type (550ng/ml) and native type (Sigma) (62.5 ng/ml) were incubated for 4 hours at 37°C in 1% BSA, pH7.75 HEPES buffer with 0.02% azide as

preservative. To measure remaining activity 1ng luciferase was added to D-luciferin substrate and luminescent counts per minute recorded.

Results are shown below in terms of remaining activity after incubation for 2 hours at 37°C and after 10 days at room temperature.

After 2 hours at 37°C:

|                                  |                        |
|----------------------------------|------------------------|
| E354K mutant luciferase          | 70% remaining activity |
| Recombinant Wild Type luciferase | 12% " " "              |
| Sigma Native luciferase          | 18% " " "              |

After 10 days at Room temperature:

|                                  |           |
|----------------------------------|-----------|
| E354K mutant luciferase          | 85% " " " |
| Recombinant Wild Type luciferase | 59% " " " |
| Sigma Native luciferase          | 71% " " " |

EXAMPLE 5: Preparation and stability of 354K:215L double mutant.

The double mutant 354 Lysine:215 Leucine of pPW601a *Photinus pyralis* luciferase was prepared by taking pPW601aE354K as described in Example 1 and mutating it using the oligonucleotide of SEQ ID No 4

5'-GAATCTGACGCAGAGAGTTCTATGCGG-3', wherein the underlined bases represent the mismatches that cause the mutation. This mutation was confirmed by DNA sequencing and measurement of the thermostability of the resultant luciferase as expressed in *E.coli* by a method analogous to that as described in Example 1 was carried out as in Examples 2 to 4 using pH7.8 phosphate buffer containing 1mM EDTA, 0.2% (w/v) BSA, 1mM DTT and 10% ammonium sulphate as heat inactivation medium.

At 43.5°C in the phosphate buffer there was less than 5% loss of activity over 32 minutes, while at 47°C  $t^{1/2}$  was approximately 38 minutes. At 50°C the double mutant retains 15% activity after 16 minutes incubation. Results for this inactivation test are shown graphically in Figure 12.



EXAMPLE 6: Purification of Luciferases.

*E. coli* JM109 cells expressing the recombinant wild-type or mutant luciferases were grown at 30°C in Luria Broth (LB) containing 50µg/ml ampicillin and induced with IPTG (1mM) during early log phase. Cells were harvested in mid stationary phase and resuspended in 50mM Tris-HCl pH8.0 containing 50mM KCl, 1mM dithiothreitol, 1.2mM phenylmethylsulphonylfluoride (PMSF) and 1mM EDTA (Buffer A). Cells were broken by disruption in an MSE soniprep 150 sonicator (amplitude 14µ) and the cell lysate centrifuged at 30000 x g for 30 minutes. The supernatant of the crude extract was then subjected to fractionation with ammonium sulphate with the fraction precipitated between 35% and 55% saturation being found to contain luciferase activity and being dissolved in Buffer A.

The extract was desalted using a Pharmacia PD10 column equilibrated in 50mM Tris-HCl pH8.0 containing 0.5mM DTT (Buffer B) and the desalted extract applied to a Pharmacia Mono Q anion-exchange column and eluted with a linear gradient of 0 to 500mM NaCl in Buffer B at a flow rate of 4ml/minute in 2 ml fractions. The peak fraction of luciferase activity was collected and dialysed against 25mM sodium phosphate buffer, pH7.5, containing 0.5mM DTT and 12% (v/v) glycerol for long term storage.

EXAMPLE 7: Heat inactivation of purified luciferases.

Eppendorf tubes containing cell free extracts of luciferase were prepared as described in Example 6. Purified preparations of luciferase (50µg/ml) were incubated in thermostability buffer comprising 50mM potassium phosphate buffer pH7.8 containing 10% saturated ammonium sulphate, 1mM dithiothreitol and 0.2% bovine serum albumin (BSA). At set times a tube was removed and cooled in an ice/water bath prior to assay with remaining assayed activity being calculated as a percentage of the initial activity.

Arrhenius plots for purified recombinant wild-type and thermostable

luciferases were constructed by measuring the half-life for inactivation in thermostability buffer over a range of temperatures from 42°C to 50°C. The natural log of  $t_{1/2}$  in minutes was then plotted against  $1/K$ . For an equivalent rate of inactivation the E354K mutation increases thermostability by 2°C at temperatures in this range as compared with an increase of 5°C with the A215L mutation and 6°C for the double mutant E354K+A215L; the latter showing the additive nature of the double mutation.

EXAMPLE 8: Increased expression of mutant luciferases as compared to wild-type recombinant luciferase in E.coli.

Expression of luciferase in *E. coli* JM109 cells was monitored during growth in liquid culture at 37°C. Cells expressing the thermostable mutants being found to accumulate more active luciferase during growth than cells expressing the recombinant wild-type enzyme. Figure 13 shows this effect graphically in plotting luciferase activity with increasing optical density at 600nm for cultures of recombinant wild-type, E354K+A215L double mutant and E354K. It can be seen that the increased thermostability of the single and double mutant allows increased production of luciferase at the 37°C culture temperature.

EXAMPLE 9: Effect of buffer on stability of mutant luciferases at 37°C.

10ng/ml solutions of each of the A215L, E354K, E354+A215L, recombinant wild-type and sigma luciferases were prepared in HEPES pH7.75 buffer with 1% BSA and 0.02% azide and thermostability at 37°C compared to that of the same compositions with addition of 2mM EDTA and 2mMDTT. Results are shown graphically in Figures 14 and 15 indicating that the relative stability of A215L and E354K varies with buffer at 37°C.

EXAMPLE 10: Effect of amino acid substitution on wavelength of light emitted in oxidation of D-luciferin.

The wavelength of light emitted on oxidation of D-luciferin with the various luciferases of the invention set out in Example 3 was measured and found to vary with the amino acid mutation. The

wavelength of light emitted varied 5nm between recombinant wild-type (E354) and E354K, and about 15nm between E354K and E354I.

Wild-type recombinant E. coli organisms give a yellow green luminescence in the presence of D-luciferin. Colours emitted by the respective mutant E. coli when provided with D-luciferin were as follows:

|       |               |
|-------|---------------|
| E354G | yellow-green  |
| E354N | yellow-green  |
| E354A | green         |
| E354V | orange-red    |
| E354M | orange-red    |
| E354F | yellow-green  |
| E354L | yellow        |
| E354Y | yellow-green  |
| E354S | yellow-green  |
| E354C | yellow-green  |
| E354K | yellow        |
| E354Q | yellow-green  |
| E354W | yellow-green  |
| E354T | yellow-green  |
| E354P | orange        |
| E354R | yellow-orange |
| E354H | yellow-green  |
| E354N | yellow        |
| E354I | red           |

## SEQUENCE LISTING

- (1) GENERAL INFORMATION:
- (i) APPLICANT:
- (A) NAME: THE SECRETARY OF STATE FOR DEFENCE IN HER  
BRITANNIC MAJESTY
- (B) STREET: WHITEHALL
- (C) CITY: LONDON
- (E) COUNTRY: UNITED KINGDOM (GB)
- (F) POSTAL CODE (ZIP): SW1A 2HB
- (A) NAME: CHRISTOPHER ROBIN LOWE
- (B) STREET: UNIVERSITY OF CAMBRIDGE; TENNIS COURT ROAD
- (C) CITY: CAMBRIDGE
- (D) STATE: CAMBRIDGESHIRE
- (E) COUNTRY: UNITED KINGDOM (GB)
- (F) POSTAL CODE (ZIP): CB2 1QT
- (A) NAME: PETER JOHN WHITE
- (B) STREET: UNIVERSITY OF CAMBRIDGE; TENNIS COURT ROAD
- (C) CITY: CAMBRIDGE
- (D) STATE: CAMBRIDGESHIRE
- (E) COUNTRY: UNITED KINGDOM (GB)
- (F) POSTAL CODE (ZIP): CB2 1QT
- (A) NAME: JAMES AUGUSTUS HENRY MURRAY
- (B) STREET: UNIVERSITY OF CAMBRIDGE; TENNIS COURT ROAD
- (C) CITY: CAMBRIDGE
- (D) STATE: CAMBRIDGESHIRE
- (E) COUNTRY: UNITED KINGDOM (GB)
- (F) POSTAL CODE (ZIP): CB2 1QT
- (A) NAME: DAVID JAMES SQUIRRELL
- (B) STREET: CBDE, PORTON DOWN
- (C) CITY: SALISBURY
- (D) STATE: WILTSHIRE
- (E) COUNTRY: UNITED KINGDOM (GB)
- (F) POSTAL CODE (ZIP): SP4 OJQ
- (ii) TITLE OF INVENTION: LUCIFERASES
- (iii) NUMBER OF SEQUENCES: 5
- (iv) COMPUTER READABLE FORM:
- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release @1.0, Version @1.25 (EPO)
- (vi) PRIOR APPLICATION DATA:
- (A) APPLICATION NUMBER: GB 9405750.2
- (B) FILING DATE: 23-MAR-1994
- (vi) APPLICATION NUMBER: GB 9501170.6
- (B) FILING DATE: 20-JAN-1995
- (2) INFORMATION FOR SEQ ID NO: 1:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1722 base pairs
- (B) TYPE: nucleic acid

19

(C) STRANDEDNESS: double  
 (D) TOPOLOGY: unknown  
 (ii) MOLECULE TYPE: DNA (genomic)  
 (iii) HYPOTHETICAL: NO  
 (iii) ANTI-SENSE: NO  
 (vi) ORIGINAL SOURCE:  
 (A) ORGANISM: *Photinus pyralis*  
 (ix) FEATURE:  
 (A) NAME/KEY: CDS  
 (B) LOCATION: 4..1653  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

```

CAAATGGAAG ACGCCAAAAA CATAAAGAAA GGCCCGGCGC CATTCTATCC TCTAGAGGAT      60
GGAACCGCTG GAGAGCAACT GCATAAGGCT ATGAAGAGAT ACGCCCTGGT TCCTGGAACA      120
ATTGCTTTTA CAGATGCACA TATCGAGGTG AACATCACGT ACGCGGAATA CTTCGAAATG      180
TCCGTTCTGGT TGGCAGAAGC TATGAAACGA TATGGGCTGA ATACAAATCA CAGAATCGTC      240
GTATGCAGTG AAAACTCTCT TCAATTCTTT ATGCCGGTGT TGGGCGCGTT ATTTATCGGA      300
GTTGCAGTTG CGCCCGCGAA CGACATTTAT AATGAACGTG AATTGCTCAA CAGTATGAAC      360
ATTTTCGAGC CTACCGTAGT GTTTGTTTCC AAAAAGGGGT TGCAAAAAAT TTTGAACGTG      420
CAAAAAAAT TACCAATAAT CCAGAAAATT ATTATCATGG ATTCTAAAC GGATTACCAG      480
GGATTCAGT  CGATGTACAC GTTCGTACAC TCTCATCTAC CTCCCGGTTT TAATGAATAC      540
GATTTTGTA CAGAGTCCTT TGATCGTGAC AAAACAATTG CACTGATAAT GAATTCCTCT      600
GGATCTACTG GGTACCTAA GGTGTGGCC CTTCCGCATA GAACTGCCTG CGTCAGATTC      660
TCGCATGCCA GAGATCCTAT TTTTGGCAAT CAAATCATTG CGGATACTGC GATTTTAAGT      720
GTTGTTCCAT TCCATCACGG TTTTGGAAATG TTTACTACAC TCGGATATTT GATATGTGGA      780
TTTCGAGTCG TCTTAATGTA TAGATTTGAA GAAGAGCTGT TTTTACGATC CCTTCAGGAT      840
TACAAAATTC AAAGTGCATT GCTAGTACCA ACCCTATTTT CATTCTTCGC CAAAAGCACT      900
CTGATTGACA AATACGATTT ATCTAATTTA CACGAAATTG CTTCTGGGGG CGCACCTCTT      960
TCGAAAGAAG TCGGGGAAGC GGTGCAAAA CGCTTCCATC TTCCAGGGAT ACGACAAGGA     1020
TATGGGCTCA CTGAGACTAC ATCAGCTATT CTGATTACAC CCNNNGGGA TGATAAACCG     1080
GGCGCGGTCG GTAAAGTTGT TCCATTTTTT GAAGCGAAGG TTGTGGATCT GGATACCGGG     1140
AAAACGCTGG GCGTTAATCA GAGAGGCGAA TTATGTGTCA GAGGACCTAT GATTATGTCC     1200
GGTTATGTAA ACAATCCGGA AGCGACCAAC GCCTTGATTG ACAAGGATGG ATGGCTACAT     1260

```

20

TCTGGAGACA TAGCTTACTG GGACGAAGAC GAACACTTCT TCATAGTTGA CCGCTTGAAG 1320  
 TCTTTAATTA AATACAAAGG ATATCAGGTG GCGCCCGCTG AATTGGAATC GATATTGTTA 1380  
 CAACACCCCA ACATCTTCGA CGCGGGCGTG GCAGGTCTTC CCGACGATGA CGCCGGTGAA 1440  
 CTTCCCGCCG CCGTTGTTGT TTTGGAGCAC GGAAAGACGA TGACGGAAAA AGAGATCGTG 1500  
 GATTACGTCG CCACTCAAGT AACAAACCGCG AAAAAGITGC GCGGAGGAGT TGTGTTTGTG 1560  
 GACGAAGTAC CGAAAGGTCT TACCGGAAAA CTCGACGCAA GAAAAATCAG AGAGATCCTC 1620  
 ATAAAGGCCA AGAAGGGCGG AAAGTCCAAA TTGTAAATG TAACTGTATT CAGCGATGAC 1680  
 GAAATTCTTA GCTATTGTAA TCCTCCGAGG CCTCGAGGTC GA 1722

## (2) INFORMATION FOR SEQ ID NO: 2:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 550 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Photinus pyralis*

(ix) FEATURE:

(A) NAME/KEY: Modified-site

(B) LOCATION: 354

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met Glu Asp Ala Lys Asn Ile Lys Lys Gly Pro Ala Pro Phe Tyr Pro  
 1 5 10 15  
 Leu Glu Asp Gly Thr Ala Gly Glu Gln Leu His Lys Ala Met Lys Arg  
 20 25 30  
 Tyr Ala Leu Val Pro Gly Thr Ile Ala Phe Thr Asp Ala His Ile Glu  
 35 40 45  
 Val Asn Ile Thr Tyr Ala Glu Tyr Phe Glu Met Ser Val Arg Leu Ala  
 50 55 60  
 Glu Ala Met Lys Arg Tyr Gly Leu Asn Thr Asn His Arg Ile Val Val  
 65 70 75 80  
 Cys Ser Glu Asn Ser Leu Gln Phe Phe Met Pro Val Leu Gly Ala Leu  
 85 90 95  
 Phe Ile Gly Val Ala Val Ala Pro Ala Asn Asp Ile Tyr Asn Glu Arg  
 100 105 110  
 Glu Leu Leu Asn Ser Met Asn Ile Ser Gln Pro Thr Val Phe Val  
 115 120 125

21

Ser Lys Lys Gly Leu Gln Lys Ile Leu Asn Val Gln Lys Lys Leu Pro  
 130 135 140  
 Ile Ile Gln Lys Ile Ile Ile Met Asp Ser Lys Thr Asp Tyr Gln Gly  
 145 150 155 160  
 Phe Gln Ser Met Tyr Thr Phe Val Thr Ser His Leu Pro Pro Gly Phe  
 165 170 175  
 Asn Glu Tyr Asp Phe Val Pro Glu Ser Phe Asp Arg Asp Lys Thr Ile  
 180 185 190  
 Ala Leu Ile Met Asn Ser Ser Gly Ser Thr Gly Leu Pro Lys Gly Val  
 195 200 205  
 Ala Leu Pro His Arg Thr Ala Cys Val Arg Phe Ser His Ala Arg Asp  
 210 215 220  
 Pro Ile Phe Gly Asn Gln Ile Ile Pro Asp Thr Ala Ile Leu Ser Val  
 225 230 235 240  
 Val Pro Phe His His Gly Phe Gly Met Phe Thr Thr Leu Gly Tyr Leu  
 245 250 255  
 Ile Cys Gly Phe Arg Val Val Leu Met Tyr Arg Phe Glu Glu Glu Leu  
 260 265 270  
 Phe Leu Arg Ser Leu Gln Asp Tyr Lys Ile Gln Ser Ala Leu Leu Val  
 275 280 285  
 Pro Thr Leu Phe Ser Phe Phe Ala Lys Ser Thr Leu Ile Asp Lys Tyr  
 290 295 300  
 Asp Leu Ser Asn Leu His Glu Ile Ala Ser Gly Gly Ala Pro Leu Ser  
 305 310 315 320  
 Lys Glu Val Gly Glu Ala Val Ala Lys Arg Phe His Leu Pro Gly Ile  
 325 330 335  
 Arg Gln Gly Tyr Gly Leu Thr Glu Thr Thr Ser Ala Ile Leu Ile Thr  
 340 345 350  
 Pro Xaa Gly Asp Asp Lys Pro Gly Ala Val Gly Lys Val Val Pro Phe  
 355 360 365  
 Phe Glu Ala Lys Val Val Asp Leu Asp Thr Gly Lys Thr Leu Gly Val  
 370 375 380  
 Asn Gln Arg Gly Glu Leu Cys Val Arg Gly Pro Met Ile Met Ser Gly  
 385 390 395 400  
 Tyr Val Asn Asn Pro Glu Ala Thr Asn Ala Leu Ile Asp Lys Asp Gly  
 405 410 415

22

Trp Leu His Ser Gly Asp Ile Ala Tyr Trp Asp Glu Asp Glu His Phe  
                     420                    425                    430  
 Phe Ile Val Asp Arg Leu Lys Ser Leu Ile Lys Tyr Lys Gly Tyr Gln  
                     435                    440                    445  
 Val Ala Pro Ala Glu Leu Glu Ser Ile Leu Leu Gln His Pro Asn Ile  
                     450                    455                    460  
 Phe Asp Ala Gly Val Ala Gly Leu Pro Asp Asp Ala Gly Glu Leu 465  
                     470                    475                    480  
 Pro Ala Ala Val Val Val Leu Glu His Gly Lys Thr Met Thr Glu Lys  
                     485                    490                    495  
 Glu Ile Val Asp Tyr Val Ala Ser Gln Val Thr Thr Ala Lys Lys Leu  
                     500                    505                    510  
 Arg Gly Gly Val Val Phe Val Asp Glu Val Pro Lys Gly Leu Thr Gly  
                     515                    520                    525  
 Lys Leu Asp Ala Arg Lys Ile Arg Glu Ile Leu Ile Lys Ala Lys Lys  
                     530                    535                    540  
 Gly Gly Lys Ser Lys Leu  
 545                    550

## (2) INFORMATION FOR SEQ ID NO: 3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Photinus pyralis
- (ix) FEATURE:
  - (A) NAME/KEY: misc-.difference
  - (B) LOCATION: replace(10, "")

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

CATCCCCCTT GGGTGTAAATC AG

22

## (2) INFORMATION FOR SEQ ID NO: 4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Photinus pyralis



23

(ix) FEATURE:  
 (A) NAME/KEY: misc\_difference  
 (B) LOCATION: replace(16..17, "")  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

GAATCTGACG CAGAGAGTTC TATGCGG

27

(2) INFORMATION FOR SEQ ID NO: 5:  
 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 550 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: unknown  
 (ii) MOLECULE TYPE: protein  
 (iii) HYPOTHETICAL: NO  
 (vi) ORIGINAL SOURCE:  
 (A) ORGANISM: Photinus pyralis  
 (ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 354  
 (ix) FEATURE:  
 (A) NAME/KEY: Modified-site  
 (B) LOCATION: 215

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Glu | Asp | Ala | Lys | Asn | Ile | Lys | Lys | Gly | Pro | Ala | Pro | Phe | Tyr | Pro | 1   | 5   | 10  | 15  |
| Leu | Glu | Asp | Gly | Thr | Ala | Gly | Glu | Gln | Leu | His | Lys | Ala | Met | Lys | Arg | 20  | 25  | 30  |     |
| Tyr | Ala | Leu | Val | Pro | Gly | Thr | Ile | Ala | Phe | Thr | Asp | Ala | His | Ile | Glu | 35  | 40  | 45  |     |
| Val | Asn | Ile | Thr | Tyr | Ala | Glu | Tyr | Phe | Glu | Met | Ser | Val | Arg | Leu | Ala | 50  | 55  | 60  |     |
| Glu | Ala | Met | Lys | Arg | Tyr | Gly | Leu | Asn | Thr | Asn | His | Arg | Ile | Val | Val | 65  | 70  | 75  | 80  |
| Cys | Ser | Glu | Asn | Ser | Leu | Gln | Phe | Phe | Met | Pro | Val | Leu | Gly | Ala | Leu | 85  | 90  | 95  |     |
| Phe | Ile | Gly | Val | Ala | Val | Ala | Pro | Ala | Asn | Asp | Ile | Tyr | Asn | Glu | Arg | 100 | 105 | 110 |     |
| Glu | Leu | Leu | Asn | Ser | Met | Asn | Ile | Ser | Gln | Pro | Thr | Val | Val | Phe | Val | 115 | 120 | 125 |     |
| Ser | Lys | Lys | Gly | Leu | Gln | Lys | Ile | Leu | Asn | Val | Gln | Lys | Lys | Leu | Pro | 130 | 135 | 140 |     |
| Ile | Ile | Gln | Lys | Ile | Ile | Ile | Met | Asp | Ser | Lys | Thr | Asp | Tyr | Gln | Gly | 145 | 150 | 155 | 160 |

24

Phe Gln Ser Met Tyr Thr Phe Val Thr Ser His Leu Pro Pro Gly Phe  
 165 170 175  
 Asn Glu Tyr Asp Phe Val Pro Glu Ser Phe Asp Arg Asp Lys Thr Ile  
 180 185 190  
 Ala Leu Ile Met Asn Ser Ser Gly Ser Thr Gly Leu Pro Lys Gly Val  
 195 200 205  
 Ala Leu Pro His Arg Thr Leu Cys Val Arg Phe Ser His Ala Arg Asp  
 210 215 220  
 Pro Ile Phe Gly Asn Gln Ile Ile Pro Asp Thr Ala Ile Leu Ser Val  
 225 230 235 240  
 Val Pro Phe His His Gly Phe Gly Met Phe Thr Thr Leu Gly Tyr Leu  
 245 250 255  
 Ile Cys Gly Phe Arg Val Val Leu Met Tyr Arg Phe Glu Glu Glu Leu  
 260 265 270  
 Phe Leu Arg Ser Leu Gln Asp Tyr Lys Ile Gln Ser Ala Leu Leu Val  
 275 280 285  
 Pro Thr Leu Phe Ser Phe Phe Ala Lys Ser Thr Leu Ile Asp Lys Tyr  
 290 295 300  
 Asp Leu Ser Asn Leu His Glu Ile Ala Ser Gly Gly Ala Pro Leu Ser  
 305 310 315 320  
 Lys Glu Val Gly Glu Ala Val Ala Lys Arg Phe His Leu Pro Gly Ile  
 325 330 335  
 Arg Gln Gly Tyr Gly Leu Thr Glu Thr Thr Ser Ala Ile Leu Ile Thr  
 340 345 350  
 Pro Xaa Gly Asp Asp Lys Pro Gly Ala Val Gly Lys Val Val Pro Phe  
 355 360 365  
 Phe Glu Ala Lys Val Val Asp Leu Asp Thr Gly Lys Thr Leu Gly Val  
 370 375 380  
 Asn Gln Arg Gly Glu Leu Cys Val Arg Gly Pro Met Ile Met Ser Gly  
 385 390 395 400  
 Tyr Val Asn Asn Pro Glu Ala Thr Asn Ala Leu Ile Asp Lys Asp Gly  
 405 410 415  
 Trp Leu His Ser Gly Asp Ile Ala Tyr Trp Asp Glu Asp Glu His Phe  
 420 425 430  
 Phe Ile Val Asp Arg Leu Lys Ser Leu Ile Lys Tyr Lys Gly Tyr Gln  
 435 440 445  
 Val Ala Pro Ala Glu Leu Glu Ser Ile Leu Leu Gln His Pro Asn Ile  
 450 455 460

25

Phe Asp Ala Gly Val Ala Gly Leu Pro Asp Asp Asp Ala Gly Glu Leu  
465 470 475 480

Pro Ala Ala Val Val Val Leu Glu His Gly Lys Thr Met Thr Glu Lys  
485 490 495

Glu Ile Val Asp Tyr Val Ala Ser Gln Val Thr Thr Ala Lys Lys Leu  
500 505 510

Arg Gly Gly Val Val Phe Val Asp Glu Val Pro Lys Gly Leu Thr Gly  
515 520 525

Lys Leu Asp Ala Arg Lys Ile Arg Glu Ile Leu Ile Lys Ala Lys Lys  
530 535 540

Gly Gly Lys Ser Lys Leu  
545 550

CLAIMS.

1. A protein having luciferase activity and having over 60% homology of amino acid sequence to luciferase from Photinus pyralis, Luciola mingrelica, Luciola cruciata or Luciola lateralis characterised in that the amino acid residue corresponding to residue 354 of Photinus pyralis luciferase or residue 356 of Luciola mingrelica, Luciola cruciata and Luciola lateralis luciferase is an amino acid other than glutamate.
2. A protein as claimed in claim 1 characterised in that it comprises an amino acid sequence XGDDKPGA wherein X is the amino acid residue other than glutamate.
3. A protein as claimed in claim 2 characterised in that it comprises an amino acid sequence TPXGDDKPGA wherein X is the amino acid residue other than glutamate.
4. A protein as claimed in claim 1, 2 or 3 characterised in that the amino acid X is not glycine, proline or aspartic acid.
5. A protein as claimed in claim 1, 2 or 3 characterised in that the amino acid X is one of tryptophan, valine, leucine, isoleucine and asparagine or an analogue or modification of any of these.
6. A protein as claimed in claim 1, 2 or 3 characterised in that the amino acid X is one of lysine and arginine or an analogue or modification of these.
7. A protein comprising an amino acid sequence as described in SEQ ID No 2 wherein Xaa is an amino acid as listed in any one of claims 5 or 6 or an analogue or modification thereof.
8. A DNA encoding for a protein as claimed in any one of claims 1 to 7.

9. A DNA as claimed in claim 8 comprising a nucleotide sequence as described in SEQ ID No 1 wherein the three bases N at 1063 to 1065 form a codon encoding for an amino acid other than glutamate.
10. A DNA as claimed in claim 9 wherein the codon encodes for an amino acid, analogue or modification as listed in claim 5 or 6.
11. A vector comprising a *luc* gene encoding for a protein as claimed in any one of claims 1 to 7.
12. A vector as claimed in claim 11 obtainable by treating a vector containing a wildtype or recombinant *luc* gene by site directed mutagenesis to change the codon responsible for encoding for the glutamate at position 354 of *Photaxis pyralis* luciferase or the glutamate at position 356 of *Luciola mingrelica*, *Luciola cruciata* or *Luciola lateralis* luciferase to an alternative amino acid, analogue or modification thereof.
13. A vector as claimed in claim 12 wherein the alternative amino acid is an amino acid, analogue or modification as listed in any one of claims 5 or 6.
14. A vector as claimed in any one of claims 9 to 13 selected from pKK223-3, pDR540 and pT7-7 into which a *luc* gene has been ligated.
15. A cell capable of expressing a protein as claimed in any one of claims 1 to 7 comprising DNA or a vector as claimed in any one of claims 8 to 14.
16. A cell as claimed in claim 15 being an *E. coli*, *S. cerevisiae* or an insect cell.
17. A test kit for performance of an assay through measurement of ATP characterised in that the kit comprises a protein as claimed in any one of claims 1 to 7 contained within a luminescent reagent.

18. An assay method wherein ATP is measured using luciferin and luciferase to generate light the quantity of which is related to the amount of ATP characterised in that the luciferase is a protein as claimed in any one of claims 1 to 7.

19. An assay method as claimed in claim 18 wherein the assay is carried out at a temperature of from 30°C to 70°C.

20. An assay method as claimed in claim 18 wherein the assay is carried out at a temperature of from 37°C to 60°C

21. An assay method as claimed in claim 18 wherein the assay is carried out at a temperature of from 40°C to 50°C.

22. A luciferase preparation that retains 85% or more of its luciferase activity when stored at room temperature for 10 days at room temperature in the absence of thermostabilising agent.

23. Use of a luciferase as claimed in any one of claims 1 to 7 or 22 as a label for a specific binding reagent.

24. A test kit characterised in that it comprises a specific binding reagent labelled with a luciferase as claimed in any one of claims 1 to 7.

25. Use of a luciferase encoding DNA or vector as claimed in any one of claims 8 to 14 for the purpose of reporting the identity of a cell or DNA.

Fig.1.





Fig.2.



2/8

Fig.3.






Fig.4.






3/8



HEAT INACTIVATION OF RECOMBINANT AND WILD-TYPE (SIGMA) LUCIFERASES.  
ENZYMES WERE INCUBATED FOR 20min AS DESCRIBED IN METHODS.

Fig.6.




LUCIFERASE ACTIVITY IN CRUDE EXTRACTS OF E. COLI BL21 (DE3) pPW304  
DURING GROWTH AT DIFFERENT TEMPERATURES

SUBSTITUTE SHEET (RULE 26)


4/8

Fig.7.



HEAT INACTIVATION OF LUCIFERASE 304 AND 304M-1.  
 ENZYMES WERE INCUBATED FOR 20min AS DESCRIBED IN METHODS.


Fig.8.





TIME DEPENDENT INACTIVATION OF LUCIFERASES AT 37°C

SUBSTITUTE SHEET (RULE 26)

Fig.9.





7/8

Fig.12.




STABILITY OF LUCIFERASES AT 37°C

Fig.13.



8/8

Fig.14.



STABILITY OF LUCIFERASE MUTANTS AT 37°C




Fig.15.

SUBSTITUTE SHEET (RULE 26)

## INTERNATIONAL SEARCH REPORT

Inter national Application No  
PCT/GB 95/00629

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C12N15/53 C12N9/02 G01N33/50 C12Q1/68 C12N1/19  
C12N1/21 C12N5/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N G01N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages                                       | Relevant to claim No.       |
|------------|--|-----------------------------|
| X          | EMBL Database, Accession No.: X65316,<br>Identification: CVPGEMLUC,<br>Promega cloning vector pGEM-luc<br>see bp 693-695 | 1-5,<br>7-13, 15,<br>16, 22 |
| X          | EP, A, 0 524 448 (KIKKOMAN CORPORATION) 27<br>January 1993<br>cited in the application<br>see the whole document         | 22                          |

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

14 July 1995

Date of mailing of the international search report

01.08.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Esen, J

**Information on patent family members**

PCT/GB 95/00629

Form PCT/ISA/210 (patent family annex) (July 1992)



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**